Venous thromboembolism prophylaxis in hematopoietic stem cell transplantation patients: an international web-based survey of healthcare providers

Zeidan, Amer M.; Wellman, Jessica C.; Forde, Patrick M.; Bolaños-Meade, Javier; Streiff, Michael B.

doi:10.1007/s11239-013-1002-0

Cited by 4 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most cases of VTE occur within 6-12 months of HSCT [138]. Among VTE, asymptomatic catheter-related thrombosis is the most common (19-41%) and symptomatic thrombosis in only 1-4% of patients [145,146]. While lower extremity deep vein thrombosis and pulmonary embolism was associated with an increased risk of nonrelapse mortality (hazard ratio of 1.7), upper extremity or catheter-related thrombosis was not [140].…”

Section: Venous Thromboembolic Diseasementioning

confidence: 99%

“…Despite the risk of VTE during the post-transplant period, VTE prophylaxis is not generally used in HSCT recipients [135]. Current practice of VTE prophylaxis varies significantly between institutions but utilisation rates of pharmacologic VTE prophylaxis are generally low (about 15%) in both North America and internationally [145]. Carefully designed prospective interventional trials of thromboprophylaxis after HSCT are needed, targeting the subsets of patients that we have identified as being at the highest risk of VTE.…”

Section: Venous Thromboembolic Diseasementioning

confidence: 99%

See 1 more Smart Citation

Noninfectious pulmonary complications of haematopoietic stem cell transplantation

2020

View full text Add to dashboard Cite

Haematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignant and nonmalignant conditions. Pulmonary complications, both infectious and noninfectious, are a major cause of morbidity and mortality in patients who undergo HSCT. Recent advances in prophylaxis and treatment of infectious complications has increased the significance of noninfectious pulmonary conditions. Acute lung injury associated with idiopathic pneumonia syndrome remains a major acute complication with high morbidity and mortality. On the other hand, bronchiolitis obliterans syndrome is the most challenging chronic pulmonary complication facing clinicians who are taking care of allogeneic HSCT recipients. Other noninfectious pulmonary complications following HSCT are less frequent. This review provides a clinical update of the incidence, risk factors, pathogenesis, clinical characteristics and management of the main noninfectious pulmonary complications following HSCT.

show abstract

Section: Venous Thromboembolic Diseasementioning

confidence: 99%

Section: Venous Thromboembolic Diseasementioning

confidence: 99%

Noninfectious pulmonary complications of haematopoietic stem cell transplantation

2020

View full text Add to dashboard Cite

show abstract

“…20 Presence of thrombocytopenia and bleeding complications in the immediate post-transplant period preclude the use of anticoagulation, which may also increase the risk of VTE. 21,22 Cardiovascular risk factors (CVRFs) such as diabetes, hypertension and dyslipidemia are common in long-term survivors of allogeneic BMT, and manifest at an earlier age. 23 In addition, BMT survivors are at increased risk of developing atherosclerosis and arterial vascular events, especially in the presence of CVRFs.…”

Section: Discussionmentioning

confidence: 99%

Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model

et al. 2021

View full text Add to dashboard Cite

Background: Allogeneic blood or marrow transplant (BMT) recipients are at risk for venous-thromboembolism (VTE) because of high-intensity therapeutic exposures, comorbidities and a pro-inflammatory state due to chronic graft vs. host disease (GvHD). The long-term risk of VTE in allogeneic BMT survivors remains unstudied. Methods: Participants were drawn from the BMT Survivor Study (BMTSS), a retrospective cohort study that included patients who underwent transplantation between 1974 and 2014 and survived ≥2y after BMT. The BMTSS survey collected information on sociodemographics, health behaviors and chronic health conditions along with age at diagnosis. Details regarding primary cancer diagnosis, transplant preparative regimens, type of transplant and stem cell source were obtained from institutional databases and medical records. We analyzed the risk of VTE in 1,554 2y survivors of allogeneic BMT compared to 907 siblings. Using backward variable selection guided by minimizing Akaike's information criterion, we created a prediction model for risk of late-occurring VTE. Results: Allogeneic BMT survivors had a 7.3-fold higher risk of VTE compared to siblings (95%CI: 4.69-11.46, p<0.0001). After a median follow-up of 11y (inter-quartile range: 6-18y), and conditional on surviving the first 2y after BMT, the cumulative incidence of late-occurring VTE was 2.4% at 5y, 4.9% at 10y and 7.1% at 20y after BMT. Older age at BMT (hazard ratio [HR]=1.02/y, 95%CI=1.01-1.04, p=0.002), use of immunosuppressive medications (HR=2.28, 95%CI=1.41-3.38, p=0.0008), obesity (HR=1.06/unit increase in body mass index, 95%CI=1.02-1.10, p=0.002), history of stroke (HR=3.71, 95%CI=1.66-8.27, p=0.001), chronic GvHD (HR=1.62, 95%CI=1.00-2.60, p=0.049), and use of peripheral blood stem cells (PBSCs) as source of stem cells compared to bone marrow (HR=2.73, 95%CI=1.65-4.50, p<0.0001) were associated with increased VTE risk. The final model for VTE risk applied at 2y post-BMT ("HiGHS2") included History of stroke, chronic GvHD, Hypertension, Sex (male vs. female) and Stem cell source (PBSCs vs. other) (corrected C-statistics: 0.73; 95%CI=0.67-0.79), and was able to classify patients at high and low VTE risk (10y cumulative incidence 9.3% vs. 2.4%, p<0.0001). Conclusions: The BMTSS HiGHS2 risk model when applied at 2y post-BMT can be used to inform targeted prevention strategies for patients at high risk for late-occurring VTE.

show abstract

Late non‐infectious pulmonary complications

Soubani

2021

Blood and Marrow Transplantation Long Term Management

View full text Add to dashboard Cite

Venous thromboembolism prophylaxis in hematopoietic stem cell transplantation patients: an international web-based survey of healthcare providers

Cited by 4 publications

References 5 publications

Noninfectious pulmonary complications of haematopoietic stem cell transplantation

Noninfectious pulmonary complications of haematopoietic stem cell transplantation

Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model

Late non‐infectious pulmonary complications

Contact Info

Product

Resources

About